SCHEMBL23977888

SCHEMBL23977888

Cc1ccc(C)c(OCC(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.58
TSHR P16473 3/20 0.49
TDP1 Q9NUW8 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TTR P02766 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C8 P10632 1/20 0.46
CHRM1 P11229 1/20 0.46
ADRA1A P35348 1/20 0.46
PPARG P37231 1/20 0.46
HTR2B P41595 1/20 0.46
PPARA Q07869 1/20 0.46
SLCO1B3 Q9NPD5 1/20 0.46
CISD1 Q9NZ45 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 2/20 0.46
USP2 O75604 2/20 0.46
MAPT P10636 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12017707 0.85 L3MBTL1 (0.46) CYP2C9TSHRSMN1; SMN2CYP1A2LMNA
SCHEMBL12598685 0.83 FFAR1 (0.46) CYP2C9SMN1; SMN2CYP1A2ADRA1AHTT
SCHEMBL68550 0.83 ALDH1A1 (0.44) CYP2C9CYP1A2ALDH1A1USP2MAPT
SCHEMBL10285683 0.83 ALDH1A1 (0.51) CYP2C9SMN1; SMN2CYP1A2HTTALDH1A1
SCHEMBL17446177 0.82 CYP2C9 (0.65) CYP2C9TSHRTDP1SMN1; SMN2TTR
SCHEMBL8279777 0.81 MAPT (0.50) CYP2C9TDP1SMN1; SMN2CYP1A2PPARG
SCHEMBL13178887 0.81 MAPT (0.54) CYP2C9TDP1SMN1; SMN2CYP1A2HTT
SCHEMBL17316513 0.81 HRH4 (0.44) CYP2C9CYP1A2ALDH1A1USP2MAPT
SCHEMBL23977884 0.81 ACHE (0.59) CYP2C9TDP1SMN1; SMN2CYP1A2ALDH1A1
SCHEMBL7830384 0.81 ALDH1A1 (0.61) CYP2C9TDP1SMN1; SMN2CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230136562-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 US disclosed
US-20230136562-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 US disclosed
WO-2021219594-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136562-A1 SPIROUREA DERIVATIVES KCNA7, PKD2, KCNN3 CYP2C9 661/4885TSHR 778/4885TDP1 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.